BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 17255787)

  • 1. Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances.
    Mrózek K; Döhner H; Bloomfield CD
    Curr Opin Hematol; 2007 Mar; 14(2):106-14. PubMed ID: 17255787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review.
    Baldus CD; Mrózek K; Marcucci G; Bloomfield CD
    Br J Haematol; 2007 Jun; 137(5):387-400. PubMed ID: 17488484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy of acute myeloid leukemia: towards a patient-oriented, risk-adapted approach.
    Mandelli F; Petti MC; Lo Coco F
    Haematologica; 1998 Nov; 83(11):1015-23. PubMed ID: 9864924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives.
    Falini B; Sportoletti P; Martelli MP
    Curr Opin Oncol; 2009 Nov; 21(6):573-81. PubMed ID: 19770764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression with prognostic implications in cytogenetically normal acute myeloid leukemia.
    Baldus CD; Bullinger L
    Semin Oncol; 2008 Aug; 35(4):356-64. PubMed ID: 18692686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of new prognostic markers in treatment decisions in acute myeloid leukemia.
    Schlenk RF; Döhner K
    Curr Opin Hematol; 2009 Mar; 16(2):98-104. PubMed ID: 19468271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?
    Mrózek K; Marcucci G; Paschka P; Whitman SP; Bloomfield CD
    Blood; 2007 Jan; 109(2):431-48. PubMed ID: 16960150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML).
    Santamaría C; Chillón MC; García-Sanz R; Pérez C; Caballero MD; Mateos MV; Ramos F; de Coca AG; Alonso JM; Giraldo P; Bernal T; Queizán JA; Rodríguez JN; Puig N; Balanzategui A; Sarasquete ME; Alcoceba M; Díaz-Mediavilla J; San Miguel J; González M
    Ann Hematol; 2010 May; 89(5):453-8. PubMed ID: 19943049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia.
    Lo-Coco F; Cuneo A; Pane F; Cilloni D; Diverio D; Mancini M; Testoni N; Bardi A; Izzo B; Bolli N; La Starza R; Fazi P; Iacobelli S; Piciocchi A; Vignetti M; Amadori S; Mandelli F; Pelicci PG; Mecucci C; Falini B; Saglio G;
    Haematologica; 2008 Jul; 93(7):1017-24. PubMed ID: 18508799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of cytogenetics in acute myeloid leukemia.
    Mrózek K; Heinonen K; de la Chapelle A; Bloomfield CD
    Semin Oncol; 1997 Feb; 24(1):17-31. PubMed ID: 9045301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations of NPM1 gene in de novo acute myeloid leukaemia: determination of incidence, distribution pattern and identification of two novel mutations in Indian population.
    Ahmad F; Mandava S; Das BR
    Hematol Oncol; 2009 Jun; 27(2):90-7. PubMed ID: 19365794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genes predictive of outcome and novel molecular classification schemes in adult acute myeloid leukemia.
    Verhaak RG; Valk PJ
    Cancer Treat Res; 2010; 145():67-83. PubMed ID: 20306246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insight into the molecular pathogenesis of myeloid malignancies.
    Haferlach T; Bacher U; Haferlach C; Kern W; Schnittger S
    Curr Opin Hematol; 2007 Mar; 14(2):90-7. PubMed ID: 17255785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization of acute myeloid leukemia and its impact on treatment.
    Frankfurt O; Licht JD; Tallman MS
    Curr Opin Oncol; 2007 Nov; 19(6):635-49. PubMed ID: 17906465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association.
    Renneville A; Boissel N; Zurawski V; Llopis L; Biggio V; Nibourel O; Philippe N; Thomas X; Dombret H; Preudhomme C
    Cancer; 2009 Aug; 115(16):3719-27. PubMed ID: 19536888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of cytogenetic findings in adults with acute myeloid leukemia.
    Mrózek K; Heinonen K; Bloomfield CD
    Int J Hematol; 2000 Oct; 72(3):261-71. PubMed ID: 11185980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study.
    Marcucci G; Baldus CD; Ruppert AS; Radmacher MD; Mrózek K; Whitman SP; Kolitz JE; Edwards CG; Vardiman JW; Powell BL; Baer MR; Moore JO; Perrotti D; Caligiuri MA; Carroll AJ; Larson RA; de la Chapelle A; Bloomfield CD
    J Clin Oncol; 2005 Dec; 23(36):9234-42. PubMed ID: 16275934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution.
    Chou WC; Tang JL; Lin LI; Yao M; Tsay W; Chen CY; Wu SJ; Huang CF; Chiou RJ; Tseng MH; Lin DT; Lin KH; Chen YC; Tien HF
    Cancer Res; 2006 Mar; 66(6):3310-6. PubMed ID: 16540685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia.
    Falini B; Mecucci C; Saglio G; Lo Coco F; Diverio D; Brown P; Pane F; Mancini M; Martelli MP; Pileri S; Haferlach T; Haferlach C; Schnittger S
    Haematologica; 2008 Mar; 93(3):439-42. PubMed ID: 18268276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
    Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U
    Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.